AI is about to change healthcare. These 7 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Trisura Group, you need to believe in its ability to grow specialty insurance profitably while managing underwriting and catastrophe risk, particularly in its U.S. book. The latest results show higher earnings and EPS, but they do not materially change the near term focus on disciplined U.S. expansion as a key catalyst or the risk that rapid scaling could pressure reserves and margins if execution slips.
The recent CA$200 million senior unsecured notes issue in March 2026 is most relevant here, as it supports Trisura’s growth plans just as earnings trend higher. That added financial flexibility may help fund expansion in U.S. specialty and surety, but it also reinforces the need to watch how higher leverage interacts with underwriting risk and the company’s push for scale.
Yet investors should also be aware that if U.S. specialty growth runs ahead of risk controls and reserve discipline, then...
Read the full narrative on Trisura Group (it's free!)
Trisura Group's narrative projects CA$4.2 billion revenue and CA$191.6 million earnings by 2029. This requires 9.7% yearly revenue growth and an earnings increase of about CA$40.9 million from CA$150.7 million.
Uncover how Trisura Group's forecasts yield a CA$57.47 fair value, a 34% upside to its current price.
Simply Wall St Community members have only two fair value estimates for Trisura, spanning from CA$57.47 to CA$87.53 per share, showing strikingly different expectations. You should weigh these views alongside the execution risk in Trisura’s U.S. expansion, since that focus could influence both earnings quality and how the market ultimately prices the business.
Explore 2 other fair value estimates on Trisura Group - why the stock might be worth over 2x more than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com